The METiS platform (AiTEM) combines state-of-the-art AI data-driven algorithms, mechanism- driven quantum mechanics and molecular dynamics simulations to calculate Active Pharmaceutical Ingredient (API) properties, elucidate API-target and API-excipient interactions, and predict chemical, physical and pharmacokinetic properties of small molecule and nucleic acid therapeutics in specific microenvironments. This enables efficient lead optimization, candidate selection and formulation design. Founded by a team of MIT researchers, serial entrepreneurs and biotech industry veterans, METiS develops and in-licenses novel assets with high therapeutic potential that could benefit from its data-driven platform.
Sectors
Collaborations & Partnerships- R&D
Collaborations & Partnerships-Manufacture
Collaborations & Partnerships-Services
Gene/RNA Delivery Technology
Proprietary Research & Manufacture
Category/Key Word(s)
Drug Development Services
Lipid Nanoparticles (LNPs)
Platform Technology-Drug Discovery
Platform Technology-Drug Development
